瑞士Stalicla公司在自闭症药物开发方面得到2M美元投资,Addex公司首席执行官加入董事会。 Swiss firm Stalicla gets $2M investment for autism drug development, with Addex CEO joining board.

瑞士一家生物技术公司Stalicla收到了由Addex治疗公司牵头的200万瑞士法郎投资,用于推进其神经发育紊乱的精密药物。 A Swiss biotech firm, Stalicla, has received a 2 million Swiss Franc investment led by Addex Therapeutics to advance its precision medicine for neurodevelopmental disorders. 这笔资金将支助Stalicla以自闭症为重点的药物候选人,包括STP1和STP7(Mavoglurant),因为该公司正在筹备C系列融资。 The funding will support Stalicla's autism-focused drug candidates, including STP1 and STP7 (mavoglurant), as the company prepares for Series C financing. Addex的首席执行官Tim Dyer 加入Stalicla的董事会 并被提名为主席 Addex's CEO, Tim Dyer, joins Stalicla's board and is nominated as chairman.